Objective: Surgical aortic valve replacement is the gold standard of treatment for symptomatic severe aortic stenosis in all age groups. Transcatheter aortic valve implantation (TAVI), which is performed by senior interventional cardiologists in experienced centers, is an alternative therapy for patients considered to be at high risk for surgery. The aim of this study is to describe the procedural success and shortterm results of TAVI performed by young interventional cardiologists in Trabzon, Turkey.
Introduction
Aortic stenosis, the obstruction of blood flow across the aortic valve, has several etiologies, including congenital, senile (degenerative) and rheumatic causes. Calcific aortic stenosis is present in 3-5% of adults over 75 years in industrialized countries and currently is the most common valvular disease due to increasing life expectancies [1, 2] .
Surgical aortic valve replacement (SAVR) is currently the gold standard of treatment for symptomatic severe aortic stenosis in all age groups [3] . Without surgical intervention, the mortality rate of patients with severe aortic stenosis increases from the onset of symptoms, rising to 25% at 1 year and 50% at 2 years. More than 50% of deaths are sudden [3] . A third of patients with aortic stenosis are not suitable for SAVR because of advanced age, left ventricle dysfunction, reduced pulmonary functions, and other comorbidities. Neither medical treatment nor percutaneous balloon aortic valvuloplasty have been shown to reduce mortality in these patients.
Trancatheter aortic valve implantation (TAVI) is a new treatment option for high-risk patients. The first human TAVI procedure was performed with a balloon-expandable device by Cribier in April 2002 [4] . The Edwards Lifesciences SAPIEN THV device is a balloon-expandable valve. It has three leaflets made of bovine pericardium, and the balloon is mounted on the tip of large delivery catheter. The valve is sewn onto the stainless steel balloon-expandable stent and is firmly crimped over the balloon before implantation [5] .
Two large registries, PARTNER (Placement of AoRTic traNscathetER) and SOURCE (SAPIEN Aortic Bioprosthesis European Outcome), have been published and have shown excellent short-and mid-term results after TAVI [6, 7] . The European System for Cardiac Operative Risk Evaluation (EuroSCORE) [8] and the Society of Thoracic Surgeons (STS) [9] now offer TAVI for the effective treatment of patients who are at high risk for conventional open-heart surgery. The SOURCE registry revealed that the success rate of the procedure was 95% and the one-year survival rate was 69.3% and 81% for the transapical and the transfemoral approaches, respectively [7] .
The first percutaneous aortic valve implantation in Turkey was performed by Yücel G et al. [10] in 2009. Although the interest in TAVI has been growing in recent years, only a limited number of centers currently perform the TAVI procedure. Our hospital is one of the TAVI centers in Turkey but in contrast to other centers in Turkey, our hospital TAVI team consists of young interventional cardiologists.
In this study, we present the initial experiences and the short-term results of TAVI with Edwards-SAPIEN THV performed by young cardiologists in our center.
Materials and Methods

Study design
A total of 11 patients, comprising 10 women and 1 man, who were treated by TAVI between January 2012 and April 2012, were included in the study. All patients were evaluated three months after the procedure. The patients' clinical and echocardiographic variables were compared before and three months after the procedure. All patients gave informed consent before enrollment, and the study protocol was approved by the Kartal Kosuyolu Yüksek İhtisas Education and Research Hospital Ethics Committee (2012/3/17).
Patient selection
The study population was comprised of patients with symptomatic severe aortic stenosis who were at high risk for open-heart surgery. Aortic valve replacement surgery was indicated, according to the guidelines from the American College of Cardiology/American Heart Association for the management of patients with valvular heart disease [3] . The best treatment option for these patients with high surgical risk was evaluated by a team consisting of two cardiovascular surgeons and three cardiologists. High surgical risk was defined by advanced age, severe obstructive airway disease, impaired renal functions, reduced left ventricular functions and other comorbidities. The patients were considered suitable for TAVI if they had a logistic EuroSCORE of >20% or a STS score of >10%, at least one-year life expectancy, resistance to medical therapy and anatomical suitability. A total of 11 patients underwent the TAVI procedure.
Patient screening
All patients underwent transthoracic and transesophageal echocardiography, thoracoabdominal and peripheral computed tomographic angiography (CTA), conventional coronary and peripheral angiography to select the appropriate intervention methods for TAVI and to determine the anatomical suitability of patients for the procedure.
Echocardiographic assessment
Comprehensive transthoracic echocardiography was performed in all patients according to the guidelines of American Society of Echocardiography [11] . Severe aortic valve stenosis was defined by echocardiography as an aortic valve area ≤0.8 cm² and/or mean pressure gradient ≥40 mmHg or peak aortic velocity ≥4 m/sec. To assess the suitability of the patients for the procedure, particular attention was given to left ventricle function, mitral regurgitation, the presence of sigmoid septum and aortic valve annulus diameter, which was measured as the distance between the hinge points of the aortic valve leaflets in the parasternal long-axis view. All patients were evaluated by transesophageal echocardiography to accurately measure the diameter of their aortic valve annulus (Figure 1 ). The valve size was determined by transesophageal echocardiographic measurements. The 23 mm and 26 mm diameter valves were used for patients whose annulus measured 18 to 21 mm and 22 to 25 mm in diameter, respectively.
Computerized tomography assessment:
CTA was used to identify the presence of heavy aortic calcification, abdominal aorta bifurcation, calcification and angulation, the distance between the left main coronary artery and bottom cusps. Angulation of less than 10 mm length was considered to be a contraindication to the procedure ( Figure  2A and 2B). Peripheral CTA was evaluated for the presence of tortuosity and calcification on both left and right common iliac artery, external iliac artery and common femoral artery ( Figure  2C and 2D). The minimal luminal diameter was measured on both sides to decide the appropriate TAVI procedure, transapical or transfemoral, and the optimal side for the transfemoral approach. The transfemoral approach was aborted if there was severe peripheral tortuosity and if minimal peripheral sizes of both the ilio-femoral arteries were smaller than 6.0 mm and 6.5 mm for 23 mm and 26 mm valves, respectively.
Coronary and peripheral angiographic assessment
All patients underwent coronary and peripheral angiography before their procedures. Selective right and left coronary angiography was performed according to the Judkins technique. Significant coronary artery disease was defined as a stenosis of above 70% luminal narrowing. Significant lesions in the proximal major epicardial arteries, which would require percutaneous coronary intervention were not observed. Aortography and peripheral angiography were performed with 6F Pigtail catheters to determine the line on which the three cusps were aligned and the presence of peripheral artery stenosis ( Figure 3A and 3B).
The procedure A catheterization laboratory, which was adapted to surgical sterilization rules, was used to perform all TAVI procedures. Extracorporeal circulation equipment was kept in the room for emergency situations. The number of personnel in the room was restricted to 3 interventional cardiologists, 1 cardiac surgeon, 1 senior interventional cardiologist to assist in the procedures, 1 anesthesiologist, 2 nurses and one technician for valve crimping. All laboratory personnel were prepared according to open-heart surgery preparation rules. All procedures were performed by transfemoral approach via the right femoral artery (RFA) under deep sedation and using Edwards SAPIEN balloon-expandable valves. In the first 8 cases, femoral access was achieved by surgical cut down. In the 3 last cases, femoral access was achieved with the Prostar XL device (Abbott Vascular Devices, Redwood City, CA, USA).
A dose of 300 mg acetylsalicylic acid was given orally at least 24 hours prior to the procedure, and antibiotic pro- phylaxis was administered in the laboratory. A dose of 300 mg clopidogrel was given postoperatively to avoid bleeding complications. Clopidogrel administration was continued for one month at 75 mg/day, and acetylsalicylic acid administration was continued indefinitely.
6F sheath introducers were placed into the left femoral artery (LFA) and vein (LFV). A pigtail catheter and a transvenous pace maker electrode were positioned in the aortic root and the right ventricle via the LFA and LFV, respectively. An Edwards e-sheath of 16F or 18F, for 23 mm and 26 mm THV, respectively, were placed to the level of the abdominal aorta over the stiff wire after RFA access was achieved. Dilators of 14F or 16F were used. A dose of 70 U/kg heparin was administered intravenously. The aortic valve was crossed with an Amplatz diagnostic catheter over the straight and soft tipped wire. The straight wire was exchanged with a preshaped, Amplatz extrastiff wire. The pacemaker was tested to capture the threshold and blood pressure level during rapid ventricular pacing (RVP). A RVP rate at which the systolic blood pressure level was less than 60 mmHg was achieved. This was considered the optimum RVP rate. During rapid ventricular pacing, balloon catheters of 20 mm and 23 mm were used to perform balloon aortic valvuloplasty for 23 mm and 26 mm THV, respectively. Aortography and balloon aortic valvuloplasty were carried out simultaneously ( Figure 4A ). The valve that was to be implanted was crimped over the balloon mounted on the tip of a large delivery catheter by the technician. The valve was delivered to the aortic annulus by means of the RetroFlex delivery system. The angiographic view, in which the three cusps are aligned, was obtained and the valve was deployed during RVP. Aortography and transthoracic echocardiography was obtained after the implantation to assess complications and paravalvular aortic regurgitation ( Figure 4B ). The delivery system and the pacemaker electrode were retrieved, and the procedure was finished.
A senior interventional cardiologist, who was experienced in TAVI, was present during all the procedures but only supported the interventional cardiology team and did not interfere during TAVI. 
Figure 5. A) Decrease of mean aortic valve pressure gradients showed in colored lines for each patients, pre-TAVI and post-TAVI (3 months after procedure). B) Aortic valve areas before and 3 months after TAVI, increase of aortic valve areas for each patients displayed in colored lines.
Kolmogorov-Smirnov test. The comparisons of continuous variables were performed using nonparametric Wilcoxon test. A p value of <0.05 was considered statistically significant.
Results
Patient population
All patients, 90.1% women and 9.9% men, had severe symptomatic aortic stenosis. The patients' baseline clinical and echocardiographic data are shown in Table 1 . The median age was 83 (80-85) years. The median calculated logistic EuroSCORE and STS scores were 28% (24%-34%) and 14% (12%-18%), respectively. Ten patients presented with New York Heart Association (NYHA) functional class III, while 1 patient presented with NYHA functional class IV. Six (54.5%) patients had angina and 4 (36.4%) patients had syncope. The left ventricular ejection fraction (LVEF) was 60 (55-65). The mean aortic valve pressure gradient was 50 (48-54) mmHg, and the median aortic valve area (AVA) was 0.60 (0.55-070) cm². All procedures were performed by three young interventional cardiologists aged thirty, thirty-one and thirty-three years. None of the patients had severe coronary artery disease. Thus, percutaneous coronary intervention had not been performed prior to the procedures.
In-hospital and procedural data
All procedures were performed with Edwards SAPIEN balloon-expandable valves via the transfemoral access route. The intraprocedural and in-hospital stay data are shown in Table 2 . The procedural success was 100%. The 23 and 26 mm valves were implanted in 9 and 2 patients, respectively. The median procedure time was 80 (70-90) minutes. The total volume of contrast agent used was 400 (210-480) mL. After the procedures, paravalvular aortic regurgitation was assessed by angiography and was observed in 5 patients (Grade 1-2). However, hemodynamic intolerability due to paravalvular regurgitation was not observed in our patients. Neither peripheral vascular nor cerebral events were observed in our study population. Subtotal obstruction of the left main coro- Prostar XL (n) 3
Intraprocedural mortality (n) 0
In-hospital mortality (n) 1
Paravalvular aortic regurgitation
Grade 1&2 (n) 5
Grade 3&4 (n) 0
Permanent atrioventricular block 1 nary artery, which occurred after valve deployment, was seen in one patient. This was stented with a bare metal stent to maintain coronary blood flow. An atrioventricular block was observed in the same patient. One patient experienced cardiac perforation after transient pacemaker implantation. This was immediately treated by pericardiocentesis, and a pigtail catheter was placed into the pericardial space for drainage. At follow up, the pericardial fluid did not increase and the hemodynamic parameters of patient remained stable. The pigtail catheter was removed after the third day and the patient did not require surgical intervention. Major bleeding requiring blood transfusion was not observed in any patients. The median hospital stay was 7 (6-8) days. The patient who was stented due to left obstruction of the main coronary artery was followed up for six days because of persistent atrioventricular block, after which the permanent pacemaker was implanted. On the eighth day, the patient died in the hospital due to acute heart failure, which could not be explained by any cause. A surgical access wound occurred in one patient, who was successfully treated with antibiotics.
Three-month follow up and echocardiographic evaluation
The overall 3-month mortality was 9.1%. Ten patients were reevaluated three months after the procedure. The patients' data before and 3 months after the procedure are shown in Table 3 . Atrioventricular blockage and strokes were not observed. The aortic valve area was significantly increased from 0.65 (0.55-0.70) cm² to 1.7 (1.6-1.8) cm² (p=0.003), while the mean aortic valve pressure was decreased from 48 (46-53) mmHg to 20 (16-23) mmHg (p=0.003) ( Figure 5) . Moreover, the patients' functional status improved from NYHA class 3-4 to NYHA class 1-2.
Discussion
This study presents our initial experience with percutaneous aortic valve implantation using balloon-expandable SAPIEN Edwards valves. Although our study population was relatively small, the results obtained from our initial experience are very similar to that which has been reported in the literature with regards to procedural success, mortality rates and post-implantation clinical and echocardiographic findings [12, 13] .
Although SAVR is the first line therapy for symptomatic severe aortic stenosis, it cannot be performed on all patients due to high surgical mortality rates, especially in patients with advanced age [14, 15] . Because of increasing life expectancy, the number of patients having high surgical risk will increase. Percutaneous aortic valve implantation, a novel and sophisticated method, has been developed to solve this problem. While only a limited number of centers currently perform TAVI, the number of centers performing this procedure is increasing. The centers that currently perform TAVI have had extensive experience with BAV and European guidelines recommend that TAVI must be restricted to centers that have had extensive experience with SAVR and BAV [16] . Percutaneous aortic valve implantations have been performed in Turkey since 2009 [10] . The number of centers performing TAVI has been increasing and some complications and solutions encountered during TAVI that were published were from Turkey [17, 18] .
Our center is the largest cardiovascular center in the Black Sea region of Turkey. It is a high-volume center for percutaneous coronary intervention, catheter therapy of structural heart disease and SAVR, although it has not had experience with BAV. Our percutaneous aortic valve implantation team consists of interventional cardiologists who are younger than those comprising other teams in Turkey. Our team is possibly the youngest team in Turkey. To avoid disadvantages due to a lack of experience with TAVI, we first obtained theoretical information about the procedure, and a multidisciplinary team was structured to include interventional cardiologists and cardiovascular surgeons. In our opinion, the selection and screening of patients are the most important parts of TAVI. Thus, we focused meticulously on these topics. All procedures were supervised by a skilled interventional cardiologist, who is one of the most experienced cardiologists in TAVI in Turkey.
Our initial results are similar to previously published data, although our study population was relatively small [10, 19] . To our knowledge, our study population is the oldest, with a mean patient age of 89.8±3.4. At the same time, the mean calculated logistic EuroSCORE of our study population was one of the highest. Neither cerebrovascular nor peripheral vascular complications were observed. A coronary occlusion and permanent AV block occurred in the same patient, and Class III-IV (n) 10 0 NYHA, New York Heart Association; AVA, aortic valve area; AV, aortic valve; TAVI, transcatheter aortic valve implantation unfortunately, she died in the hospital eight days after the procedure. In the three-month follow up, no complications were observed and the functional status of all patients was improved. The aortic valve area was significantly increased, while the mean aortic valve pressure gradient decreased. The procedures were performed under deep sedation, and anesthesia-related problems were not encountered. For the first case, surgical cutdown was preferred for femoral artery access due to the lack of experience with TAVI and Prostar XL. In all subsequent cases, Prostar XL was used. In our opinion, deep sedation can be safely applied for all TF procedures. However, for femoral artery access, surgical cutdown must only be selected if the operators are new to the procedure and lack experience with closure devices.
Limitations
This study has several limitations. Firstly, the study population was small. Additionally, only the immediate and shortterm results are reported. In this study, balloon-expandable valves were used; however, results of using self-expandable valves were not investigated. Further studies with increased numbers, including long-term results and different markers of outcome, are necessary to confirm our results.
In conclusion percutaneous aortic valve implantation is the mainstay treatment option for patients who are not suitable for open-heart surgery. Worldwide, this procedure is performed in increasingly large patient populations. Accordingly, in Turkey, the number of centers that perform TAVI, a new treatment option for the patients who are not suitable for SAVR, will increase. TAVI is an expensive and highly complicated procedure, and as such, it should be performed in highvolume centers and by well-educated and specialized teams.
In the future, the technological advancements in devices will likely enable TAVI to be performed in younger patients and those who are at lower risk for SAVR. Young interventional cardiologists will play important roles in the implementation of these technical advancements. Here, we have shown that in centers with high patient load, young interventional cardiologists can successfully perform TAVI when they receive the appropriate training and form teams focused on TAVI.
